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Abstract: The gut microbiome plays an important role in human health and influences the development
of chronic diseases ranging from metabolic disease to gastrointestinal disorders and colorectal cancer.
Of increasing prevalence in Western societies, these conditions carry a high burden of care. Dietary
patterns and environmental factors have a profound effect on shaping gut microbiota in real time.
Diverse populations of intestinal bacteria mediate their beneficial effects through the fermentation
of dietary fiber to produce short-chain fatty acids, endogenous signals with important roles in
lipid homeostasis and reducing inflammation. Recent progress shows that an individual’s starting
microbial profile is a key determinant in predicting their response to intervention with live probiotics.
The gut microbiota is complex and challenging to characterize. Enterotypes have been proposed using
metrics such as alpha species diversity, the ratio of Firmicutes to Bacteroidetes phyla, and the relative
abundance of beneficial genera (e.g., Bifidobacterium, Akkermansia) versus facultative anaerobes (E. coli),
pro-inflammatory Ruminococcus, or nonbacterial microbes. Microbiota composition and relative
populations of bacterial species are linked to physiologic health along different axes. We review the
role of diet quality, carbohydrate intake, fermentable FODMAPs, and prebiotic fiber in maintaining
healthy gut flora. The implications are discussed for various conditions including obesity, diabetes,
irritable bowel syndrome, inflammatory bowel disease, depression, and cardiovascular disease.
Keywords: gut microbiota; nutrition; habitual diets; Western diet; obesity; cardiometabolic risk
factors; chronic health conditions; gastrointestinal disorders; prebiotics and probiotics
1. Introduction to Gut Microbiota and Disease
The intestinal microbiome has recently been implicated in a host of chronic diseases ranging
from inflammatory bowel disease (IBD), type 2 diabetes (T2D), and cardiovascular disease (CVD) to
colorectal cancer [1–3]. The community of ~200 prevalent bacteria, virus, and fungi inhabiting the
human gastrointestinal (GI) tract provide unique metabolic functions to the host and are fundamentally
important in health and disease [4,5]. Microbiome refers to the collective genomes of all microorganisms
inhabiting an environment. While isolating and culturing each individual species is an intractable
task, a cutting-edge method of sequence analysis, metagenomics, has enabled the reconstruction of
microbial species and their function from the collective nucleotide contents contained in a stool sample.
Shotgun metagenomic sequencing analysis discovered 1952 unclassified bacteria species in the human
gut microbiome in addition to the 553 bacteria previously cultured from the gut [6]. A central question
in medicine concerns the nature of the relationship between human health and the gut microbiota,
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which refers to the community of microorganisms themselves, the relative abundance of individual
species populations, and their function.
Metagenomics and analysis of twins data has revealed that environmental factors such as diet
and household cohabitation greatly outweigh heritable genetic contributions to the composition
and function of gut microbiota [7]. Analogous to the genetic heritability statistic, Rothschild et al.
constructed a microbiome-association index. Significant associations are observed between the gut
microbiome and host phenotypes for body mass index (BMI) (25%), waist-to-hip ratio (24%), fasting
glucose levels (22%), glycemic status (25%), high-density lipoprotein (HDL) cholesterol levels (36%),
and monthly lactose consumption (36%) [7]. Compared to BMI, waist-to-hip ratio is an anthropometric
measurement of central obesity and stronger predictor of diastolic and systolic blood pressure, total
cholesterol/HDL, and triglycerides [8] as well as death from CVD [9].
The Western diet has profound effects on the diversity and populations of microbial species that
make up gut flora [10]. The U.S. is home to the largest number of immigrants in the world, many
of whom develop metabolic diseases post immigration. Earlier epidemiological evidence revealed
a fourfold increase in obesity risk is possible within 15 years of emigrating to the U.S. compared
to populations remaining in their birth country [11]. In a recent cross-sectional and longitudinal
study of a multi-generational Asian American cohort, emigrating to the U.S. was shown to reduce
gut microbial diversity and function [12]. Alpha diversity was measured using the Shannon entropy,
a quantitative index that accounts for the abundance and evenness of species residing in the host,
as opposed to species richness, which is the number of species present. Within the gram-negative
Bacteroidetes phylum, bacterial strains from the genus Prevotella, whose enzymes degrade plant fiber,
became displaced by dominant strains from the genus Bacteroides according to an individual’s time
spent in the U.S. The ratio of Bacteroides to Prevotella increased by factors of 10, correlating with the
time in decades spent in the U.S. Prior to this study, metagenomics had identified three clusters of
variation in the human gut, referred to as enterotypes [13]. The first enterotype, high in Bacteroides
and low in Prevotella, is found in individuals on a long-term Western diet high in animal protein, the
nutrient choline, and saturated fat [14]. The second enterotype is high in Prevotella, low in Bacteroides,
and associated with a plant-based diet rich in fiber, simple sugars, and plant-derived compounds.
While less distinct, a third potential enterotype was found with a slightly higher population of genus
Ruminococcus within the phylum Firmicutes. Enriched Ruminococcus is associated with irritable bowel
syndrome (IBS) [15], and transient blooms of pro-inflammatory Ruminococcus have been associated
with active flare-ups in IBD [16]. R. gnavus, a prevalent gut microbe that proliferates in IBD, has been
found to secrete a unique L-rhamnose oligosaccharide that induces tumor necrosis factor alpha (TNFα),
a major pro-inflammatory cytokine [17].
2. Microbiota, the Immune Response, and Diet in IBD
IBD is a chronic GI disorder characterized by an overactive immune response to the gut microbiome.
A serious, debilitating condition, IBD affects growth and development in children, increases the risk
of colorectal cancer, and can lead to life-threatening complications [18]. There are two forms of IBD,
Crohn’s disease and ulcerative colitis, that differ in the inflamed areas of the intestine. Normally,
anaerobic microbes in the gut derive their nutrients from fermentation of indigestible oligosaccharides
and other carbohydrates escaping proximal digestion [19]. In IBD, respiratory electron acceptors
generated as a byproduct of the inflammatory host response become environmental stressors that
support bacterial growth [20]. The disorder results in oxidative stress for the host and the microbiome,
leading to gut dysbiosis in the form of decreased community richness and proliferation of facultative
anaerobic Enterobacteriaceae and adherent invasive strains of Escherichia coli [16,20,21]. Drug therapies
for IBD have traditionally included immunosuppressants in the form of corticosteroids, antimetabolite
agents, or anti-TNF antibodies, often with ancillary administration of antibiotics [22]. An alternative
treatment, given predominantly to children, is a defined enteral nutrition formula. Dietary therapy has
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the advantage of obviating the need for immunosuppression and is thought to work by altering the
composition of gut microbiota.
A longitudinal study involving metagenomic analysis was conducted of 90 children initiating
treatment for Crohn’s disease [22]. GI symptoms, mucosal inflammation, and microbial communities
were compared for dietary and anti-TNF therapy and antibiotic use relative to healthy children.
Microbial communities separated into two clusters based on composition. The dysbiotic community
associated with active disease was characterized by increased fungal representation, increased
lactose-fermenting bacteria (Streptococcus, Lactobacillus, Klebsiella), and the presence of human DNA
in the stool (from epithelial cells and white blood cells). Crohn’s patients also had reduced relative
abundance of Prevotella and increased Escherichia compared to healthy children. Treatment with
antibiotics in the last six months was strongly associated with microbial dysbiosis [22], consistent
with earlier findings that oral antibiotics for acne are a risk factor for new onset Crohn’s disease [23].
Antibiotic-treatment was observed to enrich fungi such as Candida and Saccharomyces [22]. Treatment
with the enteral nutrition [24] or antibody therapies, on the other hand, reduced inflammation and
markedly improved gut microbiota. The relative populations of fungi were reduced within one week
of receiving the defined dietary formula, which lacked fiber [22]. Since a defined formula was effective
for restoring healthy microbiota, it is conceivable that a more general oral diet with the proper nutrition
can restore the intraluminal environment [25–27].
3. Microbial Metabolites and Short-Chain Fatty Acids
3.1. SCFA Receptor Activation
Short-chain fatty acids (SCFAs) have attracted considerable attention for their role in human
health [28]. Obligate anaerobic bacteria (phyla Firmicutes and Bacteroidetes) encode a variety of
enzymes for hydrolyzing complex carbohydrates (chains of sugar molecules) not digestible by the host
such as resistant starch and fiber. Certain genera such as Lactobacillus and Bifidobacterium specialize in
oligosaccharide fermentation, utilizing galactooligosaccharides (GOS), fructooligosaccharides (FOS),
and polysaccharide inulin [29]. Carbohydrate fermentation by anaerobes provides the host with
important SCFAs such as acetate, propionate, and butyrate [30]. Several receptors have been identified
for SCFAs such as free fatty acid receptor 3 (FFAR3 or GPR41) and niacin receptor 1 (GPR109A) [31].
GPR41 and GPR109A are G-protein coupled receptors (GPCRs) found on intestinal epithelial cells,
immune cells, and adipocytes. As endogenous agonists in GPCR signal transduction, SCFAs have
a profound effect on physiological processes [32,33] independent of delivering calories to the host
as carbon molecules [34]. GPR41 is associated with increased energy expenditure, leptin hormone
expression, and decreased food intake [31,35]. Analogous to the activity of niacin, butyrate activates
GPR109A to suppress colonic inflammation and colon cancer development [36]. Niacin is a known
lipid-lowering agent: GPR109A inhibits triglyceride hydrolysis (lipolysis) in adipocytes, lowering
blood levels of triglyceride and low-density lipoprotein (LDL) to reduce atherogenic activity. Acetate
and propionate activate cell surface receptor GPR43 to induce neutrophil chemotaxis. GPR43 is
anti-lipolysis and implicated in IBD, but contradictory results in mouse models leave doubt as to
whether an agonist or antagonist will best treat colitis [35]. There is a growing interest in pursuing
GPR41 and GPR43 as drug targets for the chronic inflammatory disorders asthma, arthritis, and
obesity [37]. Much work remains to be done to establish the appropriate disease models needed to
study these conditions.
Colonic epithelial cells (colonocytes) are the control switch separating microbial homeostasis
from gut dysbiosis [38]. It is known that antibiotics deplete microbes that ferment essential SCFAs
such as butyrate, which are normally responsible for maintaining microbial homeostasis [24,39]. The
lack of butyrate silences metabolic signaling in the gut. Mitochondrial beta-oxidation in colonocytes
becomes disabled, resulting in a transfer of oxygen, which freely diffuses across cell membranes from
the blood to the GI lumen. Oxygen in the colon then allows for pathogenic facultative anaerobes
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such as E. coli [40] to outcompete the benign obligate anaerobes that characterize a healthy gut [41,42].
Microbial homeostasis is normally maintained by peroxisome proliferator-activated receptor gamma
(PPAR-γ). PPAR-γ is a nuclear receptor activated by butyrate and other ligands, is found in adipocytes
and colonocytes, and is responsible for activating genes involved in glucose and lipid metabolism.
Lack of butyrate signaling results in nitrate electron acceptors being released into the colon, which
facultative anaerobes can also use for cell respiration, breaking down carbohydrates into carbon dioxide
rather than fermenting them [20]. Facultative anaerobes, including Proteobacteria, could further
affect nutrition by catabolizing SCFAs present in the lumen [38]. The metabolic reprogramming of
colonocytes is analogous to that of macrophages, which become polarized toward anaerobic glycolysis
in response to proinflammatory signals. In ulcerative colitis, excessive epithelial repair results in lower
PPAR-γ synthesis, which reduces beta-oxidation and increases oxygenation of colonocytes. Inflamed
mucosae in colitis patients are increased in Proteobacteria, a major phylum of gram-negative bacteria,
but decreased in gram-positive Firmicutes. Treatment with PPAR-γ agonist, however, can improve the
microbial balance [43].
3.2. Fecal Biomarkers and IBS
Fecal biomarkers such as inflammatory proteins, antimicrobial peptides, and SCFA levels are
emerging as a non-invasive screening tool for assessing and diagnosing various health conditions [44].
Patients with IBD have lower fecal levels of acetate, propionate and butyrate, and higher levels of lactic
and pyruvic acids than healthy individuals [45]. Given the relationship between bacterial fermentation
products and atherosclerosis, ongoing research aims to characterize the fecal microbiota and SCFA
signatures of individuals with high blood lipid levels [46]. High levels of isobutyric acid could be
one such biomarker for hypercholesterolemia. Colonoscopy is an invasive exam relied on in the
United States as a periodic screen for colorectal cancer [18], but annual screening is performed in many
countries using a non-invasive fecal immunochemical test, which looks for microscopic blood in the
stool [47]. Current efforts are underway to identify novel microbial biomarkers for colorectal cancer
given that it is associated with increased fecal levels of F. nucleatum, a promoter of tumorigenesis [3].
Unlike structural disorders such as IBD, IBS is a functional disorder and collection of GI symptoms
observed in the absence of macroscopic signs of inflammation. Despite affecting 10–15% of the
population and the potential for low quality of life, its etiology is unclear and current drug treatments
are largely ineffective [48]. Diagnosis has traditionally relied on symptom criteria, stool characteristics,
and questionnaires, once all other pathologies are ruled out [49]. The Rome criteria sets classifications
for four subtypes: IBS with predominant diarrhea (IBS-D), IBS with predominant constipation (IBS-C),
and IBS with mixed or alternating-type bowel habits (IBS-M) depending on whether >25% of bowel
movements belong to soft or hard type stool categories or both, respectively, followed by IBS unclassified
(IBS-U) [50]. It has been known for some time that IBS patients have reduced microbial diversity
compared to healthy subjects [51], see also References 6–9 in [51]. Inflammatory proteins such as human
β-defensin 2, a bactericide, have been identified as a useful fecal biomarker in IBS and IBD [48,51,52].
Lastly, the concentration difference in two SCFAs, propionic minus butyric acid, has been shown to be
positive for all four IBS subtypes but negative in healthy subjects [53].
3.3. Leaky Gut
Elevated levels of interleukin 6, a pro-inflammatory peptide cytokine, and plasma levels of
lipopolysaccharide (LPS) endotoxin, a marker of gram-negative bacterial translocation, were found
to be elevated in a subpopulation of IBS-D patients with small intestinal permeability, analogous to
that observed in celiac disease [54]. It is hypothesized that psychological stress can exacerbate the
inflammatory condition by allowing translocation of harmful bacterial products across the intestinal
epithelium. Known as “leaky gut”, a compromised epithelial barrier allows toxins and antigens in the
GI lumen to enter the bloodstream. A healthy gut flora is important in maintaining the intestinal barrier.
By increasing the expression of tight cell junction proteins, beneficial probiotics such as Lactobacillus
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and Bifidobacterium can limit the development of autoimmune diseases in genetically susceptible
individuals [55] and fatty liver disease in obese individuals [56]. In alcoholic liver disease, alcohol
consumption causes gut permeability by reducing the expression of REG3, a bactericidal protein
normally responsible for restricting the mucosal colonization of luminal bacteria [57].
3.4. Gut-Brain Interactions
In the last decade, it has been discovered that the enteric and central nervous systems are linked
via a bidirectional communication network termed the gut-brain axis. Gut-brain communication is
disrupted in the cases of IBS and microbial dysbiosis [58], in the former leading to changes in intestinal
motility and secretion and causing visceral hypersensitivity (hyperalgesia) [59]. Recurrent abdominal
pain is a hallmark characteristic of IBS. Autism spectrum disorder, which is often associated with
constipation, has been connected to gut dysbiosis in the form of an increased Firmicutes/Bacteroidetes
ratio and high levels of facultative anaerobes Escherichia/Shigella and the fungal genus Candida [60,61].
It is suggested that leaky gut contributes to the pathogenesis of autism by increasing systemic
metabolites that alter the neuroimmune and neuroendocrine systems, thus affecting the brain and
neurodevelopment [61–63].
For the last century, the ketogenic diet (KD) has been used to treat refractory epilepsy in
children’s hospitals [64], achieving a 50% reduction in seizure rates [65]. KD restricts the proportion of
carbohydrate intake to create a state of ketosis in which the body relies on ketone bodies for energy
rather than glucose. Clinical studies are now investigating the use of KD for treating neurological
conditions including autism, Alzheimer’s, and Parkinson’s disease, with promising results obtained
for small cohorts [66]. The mechanism of action was initially thought to result from the normalization
of aberrant energy metabolism associated with these disorders, but the role of the gut microbiota is
now coming into focus. A recent comparison of KD-fed conventionally raised mice versus mice treated
with antibiotics or reared germ-free revealed that alterations in the gut microbiota are required to
reproduce the anti-seizure effects of KD [67]. Following KD was observed to enrich the populations
of the anaerobic genera Akkermansia and Parabacteroides. Moreover, increased levels of the inhibitory
neurotransmitter γ-aminobutyric acid (GABA) were detected in metabolite profiles of the brain
hippocampus of KD-fed mice and were observed to be microbiota-dependent. GABA is a principal
means of reducing communication between brain cells, and neuronal excitability is enhanced in
neurological conditions such as epilepsy, anxiety, and Alzheimer’s disease [66,68]. Besides dietary
intervention, these and other observations suggest that supplementation with prebiotics or probiotics
could be used to improve cognitive symptoms associated with neurological conditions ranging from
autism to Alzheimer’s and Parkinson’s [69,70], giving rise to the notion of “psychobiotics” [71,72].
Fecal microbiota transplantation (FMT) is yet another therapeutic option, which involves the
engraftment of microbes from a healthy donor [73]. In a study of 18 autistic children, an eight-week
course of FMT resulted in behavioral improvement and an 80% reduction in GI symptoms and
abdominal pain associated with autism [74]. Outcomes remained improved when assessed eight
weeks after treatment had ended, lending support to the hypothesis that gut microbiota are at least
partially responsible for autism symptoms. Analysis of microbiota composition showed that FMT
increased overall bacterial diversity and the abundance of fermentative Bifidobacterium and Prevotella in
autistic individuals even after treatment cessation. In other clinical studies, FMT has demonstrated
a 90% success rate for treating recurrent Clostridioides difficile infection, clinical remission rates of up
to 78% in treating IBD, and symptom resolution or improvement in up to 70% of IBS patients [75].
Interest is now growing for the application of FMT in other disorders ranging from Parkinson’s to
metabolic syndrome [75,76]. In patients with metabolic syndrome, FMT was shown to improve insulin
sensitivity for those with decreased baseline microbial diversity, but the effects did not persist in the
long-term [77].
Other lines of clinical evidence on the gut-brain interaction show that gut microbiota influences the
central nervous system by alterations in the release of neuroendocrine hormones and neurotransmitter
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activity. Dysfunctions in GABA receptor signaling are implicated in anxiety and depression, and
beneficial bacteria Lactobacillus and Bifidobacterium convert the amino acid glutamate into GABA [78,79].
Metagenomic analysis of a 1054-person Flemish cohort revealed that butyrate-producing Faecalibacterium
and Coprococcus associate with higher quality of life and improved mental health, while Dialister and
Coprococcus are depleted in cases of depression [79]. To improve cognitive symptoms associated with
clinical depression and anxiety, beneficial probiotic strains of B. longum and L. helveticus have been
administered clinically with promising results [72,80]. In a study comparing young and middle-aged
mice, dietary supplementation with prebiotic inulin was observed to increase Bifidobacterium and
Akkermansia, reduce neuroinflammation and anxiety, and improve cognition in middle-aged mice [81].
The fact that alterations in gut microbiota can provide cognitive symptom relief could offer one basis
for the relationship observed between quality of diet and one’s mental health status [82].
4. Gut Microbiota and Metabolic Syndrome
4.1. Obesity, Microbial Diversity, and SCFA Supplementation
Clear links are emerging between the microbiome and its effects on host metabolism, with
profound implications for human health given the rise of obesity and metabolic syndrome in Western
society [83]. A study of four twin pairs discordant for obesity by Ridaura et al. revealed differences in
their microbiota [84], with the lean individuals exhibiting an increase in bacterial SCFA fermentation
and transformation of bile acids. To show that SCFA production was transmissible, the human fecal
microbiota was transplanted into lean and obese mice. Obese mice were also cohoused with lean
mice for 10 days, which countered weight gain due to an invasion of their microbiome by specific
members of Bacteroidetes when a low-fat diet was administered. Such findings highlight the role of
environmental factors in shaping gut microbiota and the development of obesity.
A study of human and mouse microbiota correlated obesity with differences in the relative
abundance of two dominant bacterial divisions and showed that obese individuals have an increased
capacity to harvest energy from the diet [85]. Relative to lean mice and humans, obese individuals
have an increased relative abundance of Firmicutes, and reduced abundance of Bacteroidetes. The
observation that reduced microbial diversity enhances calorie harvesting is also supported by a
metagenomic analysis comparing microbiotas belonging to identical and fraternal twins and their
mothers [86]. More recent work demonstrated that individuals with low microbial gene count
have more systemic inflammation, adiposity, insulin resistance, and dyslipidemia [87]. Low gene
count individuals gained more weight over time and were dominant in Bacteroides and Ruminococcus
genera, while 36 genera including Faecalibacterium, Bifidobacterium, Lactobacillus, and Akkermansia were
significantly associated with high gene count, lean individuals. In an analogous study involving 49
overweight or obese individuals, following an energy-restricted diet for six weeks was observed to
partially restore microbial gene richness [88].
In human and rodent studies, one species of the Verrucomicrobia phylum inversely correlates
with obesity and T2D, Akkermansia muciniphila, a mucus colonizer that can use mucin as its sole
carbon and nitrogen source in times of caloric restriction. Treatment in mice with a probiotic strain of
A. muciniphila or its prebiotic FOS was shown to reverse high fat diet-induced weight gain and insulin
resistance, increase intestinal endocannabinoids controlling inflammation and the gut barrier, and
counteract diet-induced decreases in mucus layer thickness [89]. In mouse fed a high-fat/high-sucrose
diet, polyphenol-rich cranberry extract was found to protect against metabolic syndrome and intestinal
inflammation by increasing the relative abundance of Akkermansia [90]. In humans, A. muciniphila
levels at baseline and after a six-week calorie restriction diet were observed to correlate inversely with
fasting glucose, waist-to-hip ratio, and plasma triglycerides [91]. A recent pilot study was conducted in
overweight or obese insulin-resistant volunteers. Daily oral supplementation with 1010 A. muciniphila
cells was found to improve insulin sensitivity, reduce insulinemia, and decrease body weight over a
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three-month period [92]. Such successful studies suggest that A. muciniphila could find use as a next
generation probiotic to combat metabolic syndrome [93].
Roux-en-Y gastric bypass (RYGB) surgery is one of the most effective treatments for morbid obesity
and T2D. RYGB reduces adiposity, improves glucose metabolism, increases resting energy expenditure,
and results in rapid and sustained weight loss, but these effects cannot simply be attributed to decreased
food intake and absorption [94,95]. In patients post-gastric-bypass, the abundance of Firmicutes has
been found to decrease [96]. Prevotella is observed to increase three months after surgery relative
to obese individuals, while Faecalibacterium prausnitzii is lower in diabetic subjects and correlates
negatively with low-grade inflammatory markers [97]. In a mouse model, RYGB has been shown to
restructure microbiota via a rapid and sustained increase in the relative abundance of Akkermansia
downstream of the site of surgery in the gut [94].
Jiao et al. examined the effects of orally administering doses of the SCFAs acetic, propionic, and
butyric acid to weaned pigs [98]. SCFA administration was observed to decrease serum levels of
triglycerides, total cholesterol, and insulin, while increasing serum concentrations of the leptin hormone.
Remarkably, the study demonstrated that SCFAs attenuate fat deposition by inhibiting feed intake,
reducing lipogenesis, and enhancing lipolysis. Another study of 12 men undergoing colonic infusions
showed that receiving an enema containing SCFAs can increase fasting fat oxidation and resting
energy expenditure [99]. In a healthy diet, the bacterial fermentation of fiber into SCFAs promotes
microbial diversity and is one mechanism by which high fiber intake inhibits weight gain [100,101],
even outweighing heritable contributions to obesity [102].
The metabolic effects of butyrate were measured in a study of mice fed a high-fat diet (60%
of calories from lard) [103]. Oral but not intravenous administration of butyrate was shown to act
on the gut-brain circuitry via the vagus nerve, decreasing food intake and preventing diet-induced
obesity, hyperinsulinemia, hypertriglyceridemia, and fatty liver disease. Interestingly, butyrate also
promoted fat oxidation and activated brown adipose tissue. The finding that butyrate improves energy
metabolism without eliciting any ill effects suggests that oral supplementation might be a promising
strategy for combatting cardiometabolic disease [104]. Butyrate was further shown to alter the gut
microbiota independent of the vagus nerve [103]. Specific genera within the subclass Erysipelotrichia
were significantly increased, bringing the relative abundance of the Firmicutes phylum from 26% to
32% relative to controls, while the Bacteroidetes phylum decreased from 71% to 66%. The ratio of
Firmicutes to Bacteroidetes increased by 21% upon butyrate administration. Given that Firmicutes
generally correlate with a less beneficial metabolic profile [105], it appears that specific species of
Erysipelotrichia are beneficial to host energy metabolism.
4.2. Microbiota in Diabetes
Both obesity and diabetes are characterized by insulin resistance and low-grade inflammation. A
mouse study by Cani et al. points to bacterial LPS as a causative factor of insulin resistance, obesity, and
diabetes [106]. Feeding and fasting cycles increased or decreased plasma levels of LPS, respectively,
and metabolic endotoxemia was observed in mice fed a four-week high-fat diet that increased the
proportion of gram-negative bacteria in the gut, raising plasma LPS concentration by a factor of two to
three. Endotoxemia could also be induced via subcutaneous infusion of LPS for four weeks, resulting in
weight gain and increased fasting hyperglycemia and hyperinsulinemia. LPS produces inflammation
in adipocytes through the activation of toll-like receptor 4 signaling [107]. Thus, prebiotics that improve
intestinal microbiota and reduce intestinal permeability are of potential clinical use for the treatment
of diabetes [108,109]. Randomized controlled trials have reported improvements in glycemia and
cardiovascular markers in T2D patients taking resistant starch, resistant dextrin, or inulin [110].
Consumption of dietary fiber has positive metabolic health effects including increased satiety,
decreased weight gain, and lowered blood glucose and cholesterol levels, serving to reduce the risk of
CVD and T2D [111–113]. Fiber has historically been classified as either soluble or insoluble, but plant
cell walls often contain both and this distinction does not always predict physiological function [114].
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It can be more useful to classify fibers into four categories based on whether they are readily fermented
and whether they form a viscous cross-linked gel [115]. Insoluble fiber (wheat bran) is poorly fermented
and does not alter viscosity. Soluble, nonviscous fiber (inulin, wheat dextrin, resistant starch) is readily
fermented. Conversely, viscous gel-forming fibers can be fermentable (β-glucan) or not (psyllium).
Improvements in metabolism can arise from three factors: microbial fermentation of soluble fiber into
SCFAs [33,95,100], delayed nutrient absorption and improved cholesterol/glucose due to viscous gel
formation [115,116], and the ability of insoluble fiber to reduce insulin resistance by interfering with
protein absorption [112]. In conventional rats, a high-fat diet was found to reduce butyrate formation
and increase liver cholesterol and triglyceride content compared to rats fed a low-fat diet, but these
effects could be partially reversed by adding fermentable dietary fiber to the high-fat diet [117]. In a
12-week mouse study, supplementing a high-fat diet with 10% fermentable flaxseed fiber dramatically
increased butyrate production, energy expenditure, and Bifidobacterium and Akkermansia levels, while
countering weight gain [118]. In contrast to the Western diet, consuming daily servings of fiber, fruit,
and vegetables promotes the alpha diversity of bacterial species in the gut [12,102,119–121].
Suez et al. investigated the impact of non-caloric artificial sweeteners (NAS) on glucose
tolerance [122]. Commercial formulations of saccharin, sucralose, or aspartame were added to
the drinking water of lean mice for 11 weeks. The 10% NAS solutions were well below the known toxic
doses given per kg body weight. While mice drinking water, glucose, or sucrose had similar glucose
tolerance curves, all three NAS-consuming groups developed glucose intolerance, which could be
reversed upon antibiotic treatment. NAS was also shown to induce changes in gut microbiota previously
observed in T2D; notably, the over-representation of gram-negative Bacteroides and under-representation
of gram-positive Clostridiales. Bacterial taxa were enriched in the metabolic pathways involved in
glycan degradation, contributing to enhanced capacity for energy harvest [85]. Lastly, Suez et al.
assessed long-term NAS consumption in a clinical nutrition study using a food frequency questionnaire
given to 381 non-diabetic individuals. Significant positive correlations were found between NAS
consumption and measures of metabolic syndrome including increased weight, waist-to-hip ratio,
fasting blood glucose, and hemoglobin A1c [122].
The link between NAS consumption in mice and alterations in gut microbiota lends support
to the notion that individuals can have a personalized response to dietary components based on
existing or acquired differences in their microbiota. A study of 800 healthy and prediabetic Israelis
revealed high interpersonal variability in their postprandial glucose responses to the same foods,
which could be attributed to differences in gut microbiota and other factors [123]. A machine learning
algorithm was developed by Zeevi et al. and found to accurately predict personalized glycemic
responses to real-life meals using information on blood parameters, dietary habits, anthropometric
measures, physical activity, and gut microbiota. Twenty-six new participants were then recruited for a
randomized controlled trial. The algorithm was found to be capable of choosing a personalized diet
that successfully lowered the post-meal glycemic responses for each individual [123]. An analogous
study of Midwestern Americans predicted glycemic responses once the abundances of Prevotella and
Bacteroides were taken into account [124]. Such studies highlight the significance of individual microbial
profiles in constructing therapeutic interventions, of great potential relevance to the emerging field of
personalized nutrition [125].
Finally, diabetes medications have been connected to positive changes in gut microbiota.
Metagenomic analysis of 345 Chinese volunteers revealed that diabetics have a decrease in
butyrate-producing bacteria and an increase in opportunistic pathogens relative to healthy subjects [126].
A four-month placebo-controlled study was recently performed on 40 newly diagnosed T2D
patients [127]. In individuals given the gold standard T2D drug, metformin, rapid alterations
were observed in the composition of the gut microbiome. In the entire cohort, a negative association
was observed between hemoglobin A1c blood levels and B. adolescentis, a species whose replication
rate was increased by metformin. Transfer of fecal samples before and after metformin treatment to
germ-free mice showed that improved glucose tolerance can arise solely from the metformin-altered
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microbiota. At the chemical level, the antidiabetic effects were attributed to increased microbial
production of SCFAs and changes observed in the bacterial expression of metal-binding proteins [127].
In a rodent study, mice fed a high-fat diet containing lard oil had reduced expression of sodium
glucose cotransporter-1 (SGLT1) [128]. SGLT1 is normally required for healthy glucose sensing in the
upper small intestine in order to lower endogenous glucose production by the liver. Treatment with
metformin was observed to restore SGLT1 expression and enhance intestinal glucose uptake. Metformin
also increased the abundance of Lactobacillus bacteria in the upper small intestine. The antidiabetic
effect was transmissible upon fecal transplantation, showing that the intestinal microbiota restores
SGLT1 expression and glucose sensing in untreated obese rats. Before treatment, mice consuming
the high-fat diet had a decreased abundance of gram-positive phylum Actinobacteria, while phylum
Proteobacteria and genus Escherichia were increased relative to the control group consuming regular
chow. The molecular link to SGLT1 expression is unknown, but it is likely that microbial metabolites
such as SCFAs activate glucose sensing. Metagenomic analysis of a Dutch cohort corroborated that
SCFA concentrations are higher in metformin users compared to diabetics not taking metformin [120].
Analysis of a Colombian community found that metformin users had higher levels of SCFA-producing
A. muciniphila, B. bifidum, and Prevotella [129].
A subset of patients cannot tolerate metformin due to adverse GI effects including abdominal
pain, bloating, nausea, and diarrhea. A small clinical trial was recently conducted in nondiabetic
individuals, confirming that metformin alters gut microbiota independent of glycemic status [130].
Interestingly, the bacterial abundance of 12 genera at baseline predicted whether healthy individuals
would experience adverse GI effects upon treatment with metformin. This observation provides a
glimpse at how gut microbiota, which are shaped by diet, can mediate individualized therapeutic
responses to a medication. Lastly, diabetes medication acarbose is a minimally absorbed glucoamylase
inhibitor that prevents starch digestion by humans. A mouse study monitored acarbose-treated mice
fed either a Western-style high-starch diet or a high-fiber diet rich in plant polysaccharides [131].
Analogous to metformin treatment, high doses of acarbose were sufficient to alter gut bacterial
taxa and increase butyrate production even in those consuming a high-starch diet, but the bacterial
composition quickly reverted upon cessation of acarbose treatment. Altogether, these studies suggest
that alterations in the gut microbial community are prominent contributors to the mechanism of action
in antihyperglycemic agents.
4.3. Dietary Choline and Atherosclerosis
Metabolomic analysis was used to monitor 2000 metabolites present in the blood plasma of
patients undergoing cardiac evaluation in order to identify potential predictors of CVD events [132].
Three small molecules were found to predict CVD risk: choline, trimethylamine N-oxide (TMAO),
and betaine. Each are metabolites of phosphatidylcholine, a dietary lipid found in high quantities
in egg yolk, liver, and other high-fat animal products. Choline, also called lecithin, is an essential
nutrient that is marketed as a dietary supplement. Hydrolysis of phosphatidylcholine liberates choline,
which is metabolized by gut microbes into trimethylamine (TMA) gas, which the liver in turn converts
into TMAO. In mice fed radiolabeled phosphatidylcholine, increased blood levels of TMAO were
revealed to contribute to greater arterial plaque development [132]. In another study, atherosclerosis
susceptibility could be transmitted from atherogenic-prone mouse strains to atherogenic-resistant
strains via cecal microbial transplantation [133].
The National Institutes of Health funded two prospective clinical studies on TMAO [134]. In the
first study, the phosphatidylcholine challenge, plasma levels of TMAO were observed to rise after
consumption of two eggs traced with isotope-labeled phosphatidylcholine. TMAO generation could be
suppressed by administering a weeklong course of antibiotics to reduce gut bacteria. One month after
withdrawal of antibiotics, TMAO generation returned in a follow-up choline challenge test. In a second
cohort of 4007 adults undergoing cardiac evaluation, participants with the highest quartile of fasting
plasma TMAO levels had a significantly increased risk of experiencing a major adverse CVD event
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within the three-year follow-up period (hazard ratio, 2.5, relative to lowest quartile). Another study of
patients with stable coronary artery disease found a four-fold increase in all-cause five-year mortality
risk for those in the highest TMAO quartile [135]. The atherogenicity of choline metabolite TMAO helps
explain the correlation that exists between CVD and excessive consumption of animal products [136].
A causal link between dietary cholesterol and CVD, on the other hand, has not been demonstrated and
would be difficult to prove given the fact that cholesterol-containing foods are also high in saturated
fat, with the exception of eggs and shrimp [137]. A long-term study of 29,615 participants recently
showed that consuming eggs with yolk elevates one’s CVD risk in a dose-dependent fashion [138],
with each half an egg consumed per day elevating absolute risk by 1.1% and all-cause mortality by
1.9%. One egg yolk contains 120 mg choline.
A structural analog of choline and natural product found in some foods, 3,3-dimethyl-1-butanol
(DMB), has been shown in mice to reduce TMAO levels by non-lethal inhibition of TMA lyase [139],
giving credence to the notion of “drugging the microbiome.” In a study of mice fed a Western diet, DMB
reduced plasma TMAO and prevented cardiac dysfunction, inflammation, and fibrosis, but had no effect
on body weight and dyslipidemia [140]. Efforts are underway to determine the TMA-forming potential
of different bacterial species and develop new treatment strategies for restraining the proliferation
of TMA producers [141]. L-carnitine is another trimethylamine abundant in red meat that is also
sold as a dietary supplement. Similar to choline, studies in rodents and humans show that carnitine
increases plasma TMAO levels, accelerates atherosclerosis, and increases CVD risk [142]. Interestingly,
comparison of carnitine challenge tests in habitual omnivores versus vegans/vegetarians reveals that
omnivores harbor a microbiota capable of generating 20-fold higher levels of TMAO [142,143].
The connection between TMAO and CVD has important implications for meat consumption given
that beef and pork contain 100 mg choline per 100-g serving (veal: 400 mg). Fish and chicken are not far
behind with 70–80 mg choline per serving. Some studies have observed a modest increase in relative
risk of CVD mortality (between 26% and 34%) for the highest quantile consumption of unprocessed
red meat or both processed and unprocessed red meat [144,145]. Comparative risk assessment using a
national survey, however, did not find a significant contribution for unprocessed red meat alone [146],
and an earlier meta-analysis calculated its relative risk ratio per 100-g serving to be 1.00 (95% confidence
interval: 0.81–1.23) [147]. It is likely that the quality of the comparison diet is a confounding variable
contributing to disparate findings on the contribution of meat to CVD [148].
Improved cardiovascular health has been associated with one’s degree of adherence to a
Mediterranean-style diet, which limits consumption of red meat and dairy while emphasizing
plant-based foods and healthy fats [149–151]. The relative reduction in CVD morbidity risk obtained
for those in the highest quantile of adherence to the Mediterranean diet, considering all dietary
components combined, is observed from meta-analyses to be in the vicinity of 30%, or even up to
45% for high risk populations [152]. The microbiome was recently assessed by De Filippis et al. in
123 Italian individuals habitually following omnivore, vegetarian, or vegan diets [153]. To score their
adherence to the Mediterranean diet, individuals were stratified along an 11-food unit dietary index.
Individuals consuming vegetable-based diets had higher adherence to the Mediterranean diet, were
increased in Prevotella and fiber-degrading bacteria, and had higher fecal levels of SCFAs. Omnivores
on the other hand had a higher ratio of Firmicutes to Bacteroidetes in the gut and elevated TMAO in
the urine [153].
The scientific community has also debated the extent to which red meat elevates the risk of
colorectal cancer, another condition prominent in Western society [154,155]. Gut microbiota associated
with colorectal cancer were recently shown to have an increase in genes associated with TMA lyase
and protein catabolism, while microbe carbohydrate degradation pathways were depleted [156,157].
Dietary choline is not observed to correlate with cancer incidence, while betaine, a methyl group
donor, is associated with reduced colorectal cancer risk [158]. Again, overall diet quality is likely
a significant factor. A study using a polyposis cancer model in mice showed that a high-fiber diet
increases SCFA-producing bacteria as well as the expression of butyrate receptor GPR109A, serving
Nutrients 2019, 11, 1613 11 of 40
to suppress colon carcinogenesis [159]. A case-control study conducted in China found an inverse
association between vegetable fiber intake and colorectal cancer (Q4 versus Q1 odds ratio: 0.51; 95%
confidence interval: 0.31–0.85) [160]. Strong associations were also observed for total, soluble, and
insoluble fiber intakes, but not fruit, soy, or grain fiber. A comparative risk assessment estimated that
suboptimal food group intake levels account for 38% of new colorectal cancer cases [161]. Microbial
overgrowth was recently shown to fulfill the ecological Koch’s postulates [162] of disease causation in
colorectal cancer. Rather than a specific pathogen, a matrix-enclosed ecosystem of bacteria, or biofilm,
extracted from tumor patients was found to induce tumorigenesis in mice [163].
5. Microbial Interventions
5.1. Probiotics
Probiotics are defined as “live microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” [164]. Probiotics are available over-the-counter or by prescription
containing microorganisms similar to the commensal bacteria found in the gut, most commonly
lactic acid-producing Bifidobacterium and Lactobacillus spp. As a whole, there is clinical evidence to
support the use of probiotics for treating acute infectious diarrhea, antibiotic-associated diarrhea,
C. difficile-associated diarrhea, ulcerative colitis, and irritable bowel syndrome, but not for acute
pancreatitis or Crohn’s disease [165–170]. Commonly prescribed antibiotics carry a risk of C. difficile
infection, which can cause severe complications and has an estimated treatment cost of $24,205 USD
per patient. Co-administration of probiotics, which lower the risk of C. difficile infection, has therefore
been proposed as a prophylactic whenever antibiotics are prescribed [171]. Clinical research into
probiotics is species- and often strain-specific, with particular bacteria investigated for separate disease
states [172]. Probiotic bacteria can potentially provide various health benefits through normalizing
perturbed microbiota and intestinal motility, competitively excluding pathogens, and increasing SCFA
production [173–175].
Different probiotic species have been studied for ameliorating GI symptoms, though it is not
always clear which species or strains are most beneficial [176]. Earlier work observed that the ratio of
Firmicutes to Bacteroidetes was elevated in 62 IBS patients relative to 46 control subjects in Helsinki,
Finland [177]. Surprisingly, both groups were dominant in the relative abundance of Firmicutes (90%
and 83%, respectively), leaving doubt as to the representativeness or overall health of the small cohort
(64% was estimated for an 1135-person Dutch cohort [120]). Bifidobacterium was one genus of strictly
anaerobic gram-positive Actinobacteria whose numbers were markedly decreased (16–47%) in patients
diagnosed with IBS-M, IBS-D, or IBS-C relative to healthy controls [177]. Other studies have confirmed
that probiotic supplementation with bifidobacteria results in modest improvement of GI symptoms
experienced in IBS-C and IBD patients [167,178]. Correlating microbial profiles to gut health is more
complicated for other species. Within the Firmicutes phyla, Streptococcus are found to be decreased
in IBS-C but increased in IBS-D, while Allisonella are decreased in IBS-C and IBS-D but increased
in IBS-M [15]. Genera within Bacteroidetes such as Prevotella and Bacteroides may be increased or
decreased in IBS [15,177]. It has been noted that there is a strong positive association between IBS
and small intestinal bacterial overgrowth (SIBO) [179]. This gave rise to the initial idea of treating the
condition with antibiotics, but patient response varies widely and GI symptoms may even worsen.
Recent antibiotic exposure actually correlates positively with the development of SIBO [180]. SIBO and
GI symptoms have been shown to be exacerbated in healthy individuals who switch to a high-sugar,
low-fiber diet for only seven days, leading to a decrease in small intestinal microbial diversity and an
increase in epithelial permeability [180].
One challenge with the probiotic market is that, unless specific disease-related claims are made,
commercial products are poorly regulated. Probiotics are trademarked by brand rather than by bacterial
strain, and formulations or manufacturing protocols can change over time, having a dramatic impact
on efficacy [181]. It has been shown in particular that strains within the same genus or species can have
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substantially different effects on the host, differing in their ability to grow and survive the intestinal
environment, adhere to intestinal epithelial cells, and inhibit pathogen invasion [182,183]. After the
isolation of E. coli Nissle 1917 from the stool of a World War I soldier who did not catch dysentery,
nonpathogenic strains of E. coli gained some acceptance as probiotics. E. coli is unique in that it relies
on monosaccharide and disaccharide nutrients broken down from complex carbohydrates by strict
anaerobe species of bacteria [184]. Beneficial E. coli strains have been used to treat patients suffering
from infectious diseases, likely due to their ability to outcompete enteric pathogens for nutrients [40].
Recent mouse studies give cause for caution, however. Cocolonization of E. coli O157:H7, a notorious
foodborne pathogen, with a nonpathogenic strain of E. coli in germ-free mice actually increased the
pathogen’s virulence and production of Shiga toxins, which are encoded by viral prophage genes, by
up to 12-fold [185]. In another study, probiotic E. coli Nissle 1917 was observed to undergo genomic
adaptation in response to selective and diet-dependent host pressures within a transit period of five
weeks [186] To gain advantage especially in low-diversity guts, competitive adaptations in genes were
acquired that affected intestinal adhesion and the utilization of carbohydrates and mucin components
as carbon energy sources. In mice that were previously exposed to antibiotics, the E. coli strains
acquired mutations responsible for antibiotic resistance [186]. Such studies underscore the centrally
important role that horizontal gene exchange plays in the evolution of gut bacteria [187].
Several species of Lactobacillus and Bifidobacterium have now become the staples in the field
of probiotics. Notable commercial multi-strain formulations have been subjected to clinical studies
including Visbiome® (formerly VSL#3) [188], BIO-25 [189], and Ther-Biotic®Complete [190]. Visbiome®
contains several strains from well-known probiotic species L. plantarum DSM24730, Streptococcus
thermophilus DSM24731, B. breve DSM24732, L. paracasei DSM24733, L. delbrueckii subsp. bulgaricus
DSM24734, L. acidophilus DSM24735, B. longum DSM24736, and B. infantis DSM24737. Lactobacilli and
bifidobacteria such as these have been extensively tested for their anti-inflammatory effects in colitis as
well as their beneficial effects on gut motility, particularly for the treatment of constipation [173,191–193].
While E. coli is LPS-producing, B. breve has been shown to reduce LPS-induced epithelial cell shedding,
which is observed in relapsing IBD patients [194]. Populations of Lactobacillus are reduced in alcohol
consumption and in high fat diet-induced obesity [55,195]. Supplementation with probiotic strain L.
rhamnosus GG has been shown to decrease microbial overgrowth, restore mucosal integrity, reduce
microbial translocation, and ameliorate alcohol-induced liver injury [55,196]. Lastly, the use of
probiotics has been proposed as an alternative or adjuvant to antibiotic treatment [197]. In the case of
enterohemorrhagic E. coli O157:H7, antibiotics are not effective due to the release of additional toxin.
Probiotics L. acidophilus R0052 and L. rhamnosus R0011 have been observed to prevent epithelial injury
by reducing adhesion of E. coli O157:H7 and also enteropathogenic E. coli O127:H6 [198].
A clinical study of healthy adults given the probiotic L. paracasei DG revealed that the changes
observed in the underlying gut microbiota can depend on an individual’s starting microbial profile [199].
Study participants with low initial fecal butyrate levels experienced a four-fold increase in butyrate
production and a 55% decrease in Ruminococcus, a member of the Clostridia class responsible for
degrading resistant starch. On the other hand, individuals with high starting butyrate levels experienced
a 49% decrease in butyrate production and a decrease in six Clostridia genera including Faecalibacterium,
an anti-inflammatory butyrate producer beneficial to mental health [79]. Other studies corroborate that
a patient’s initial fecal microbial pattern can help predict their response to a probiotic intervention [189],
suggesting it will one day be possible to optimize the dose of bacterial strains administered for an
individual [200]. An individual’s microbiome has also been shown to influence the production of
butyrate upon dietary supplementation with fermentable resistant starch according to which bacterial
taxa become amplified [201]. Given the relation between the microbiome and metabolic disease, current
research is now exploring probiotic interventions as an adjuvant therapy for improving cardiometabolic
profiles [202,203]. Positive results have been obtained using the multi-strain formulation Ecologic®
Barrier for T2D [204]. In rats, Ecologic® Barrier was previously shown to improve depression-related
behavior independent of consumption of a high-fat Western-style diet [205]. Ecologic® Barrier contains
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the following strains: Bifidobacterium bifidum W23, B. lactis W52, Lactobacillus acidophilus W37, L. brevis
W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19, and Lc. lactis W58. Lastly, two strains of
L. gasseri isolated from human intestine and breast milk were found to reduce visceral fat mass in
obese adults, but the effects diminished once treatment with SBT2055 was ceased, indicating that the
probiotic needs to be continually supplied [206,207].
5.2. Prebiotics
In some clinical studies, a probiotic is administered in combination with a prebiotic compound
that promotes bacterial growth, together termed a synbiotic. The requirements of a prebiotic are
that it is not digested in the upper GI tract, can be fermented by intestinal microbiota, selectively
stimulates beneficial bacteria growth and diversity, and has a positive effect on host health [208,209].
Prebiotics include FOS, GOS, and polyol sugar alcohols used as nutritive sweeteners [193,210]. Inulin
is a soluble fiber and fructan, or variable length polymer of fructose, that is indigestible to humans
and has minimal impact on blood glucose levels [211]. Believed to be most effective in nurturing the
growth of many species of probiotic [193], inulin has been tested in successful synbiotic treatments for
ulcerative colitis [191,211]. More recently, supplementation with butyrate and inulin was found to
lower diastolic blood pressure, fasting blood sugar, and waist-to-hip ratio in T2D patients [104].
Numerous studies reveal that significant health benefits can be obtained from prebiotic
administration alone [110,193,211]. Prebiotics such as GOS and FOS have been shown to improve
microbial profiles by increasing bifidobacteria and decreasing E. coli [193,212]. See Table 5 in
Reference [193] for a summary of prebiotic clinical trials. In a double-blind, randomized controlled
trial of two separate cohorts in Canada, 16 weeks of FOS-enriched inulin supplementation (8 g/day)
decreased body fat, serum triglycerides, and interleukin 6 in overweight or obese children compared to
those given an isocaloric dose of maltodextrin placebo [213]. Bifidobacteria in fecal samples increased
from 6% to 10% of mean bacterial abundance with prebiotic treatment, while Firmicutes decreased from
69% to 63% and Ruminococcus from 2.3% to 1.4%. In an animal study, rats fed a high-fat/high-sucrose
diet along with FOS experienced a normalization in insulin resistance, leptin levels, dyslipidemia,
and gut microbiota [214]. Moreover, prebiotic FOS was observed to limit knee joint damage in this
diet-induced model of osteoarthritis, to levels approaching that obtained with moderate aerobic
exercise. The effects of prebiotic therapy also depend on individual’s starting microbial profile. In
a study comparing FOS, sorghum and arabinoxylan, equally high SCFA production was observed
in volunteers whose microbiota was dominant in fiber-utilizing Prevotella, but Bacteroides-dominated
individuals showed different SCFA levels in response to each fiber [215].
Given the relationship between gut microbiota and inflammation, research is underway to
examine the effects of anti-inflammatory omega-3 polyunsaturated fatty acids (PUFAs) on microbial
diversity. Consuming a Western diet high in animal protein is known to elevate the ratio of omega-6
to omega-3 PUFAs by up to a factor of 10, producing an inflammatory response mediated by
hormone-like eicosanoids in the body [149,216]. The omega-3 PUFAs docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA), however, are inflammation-resolving and have anti-colorectal cancer
activity, see References 4–6 in [217]. Human studies show that dietary supplementation with EPA
and DHA increases the intestinal abundance of Bifidobacterium and Lactobacillus, while decreasing
Faecalibacterium [217,218]. Conflicting results were reported for the effect of omega-3 fatty acids on
the ratio of Firmicutes to Bacteroidetes phyla. Lastly, a metabolomic analysis was recently conducted
of 876 adult female twins. After adjusting for dietary fiber intake, the consumption and circulating
levels of omega-3 fatty acids were found to be significantly correlated with microbial alpha diversity as
measured by the Shannon index [219].
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6. Implications for Diet and Nutrition
6.1. Dietary and other Microbiome Covariates
A metagenomic analysis was conducted of 1135 participants from a Dutch population using deep
sequencing [120]. The sequencing data enabled the detection of associations in microbiota with 126
different environmental factors including diet, disease, and medication use. Higher intakes of total
carbohydrates were most strongly associated with decreased microbiome diversity: bifidobacteria
increased while Lactobacillus, Streptococcus, and Roseburia genera decreased. The Shannon diversity
index decreased according to intake levels of total carbohydrates, followed by sugar-sweetened
beverages, bread, beer, savory snacks, and, to a lesser extent, total fats, pulses, and legumes. Diversity
was also reduced in individuals self-reporting IBS, and antibiotic use was associated with decreases
in two species of Bifidobacterium. On the other hand, microbial diversity increased with fruit, coffee,
vegetable, and red wine intake and to a smaller extent eating breakfast and drinking tea. Red wine
consumption was associated with an increased abundance of F. prausnitzii [120], an anti-inflammatory
species implicated in lean-type, high-richness microbiota [87]. Coffee, tea, and red wine are high in
polyphenols, compounds associated with prebiotic and bifidogenic activity, see References 19–21 in
Reference [120]. In a recent meta-analysis, consuming up to three cups/day in coffee was found to
decrease all-cause and CVD mortality in a dose-dependent fashion irrespective of caffeine content [220].
A similar population-level analysis of an 1106-person Belgian cohort across 69 covariates [221]
showed that the Bristol stool scale, an indicator of gut transit time, and the use of medications have
the largest explanatory value for microbiome variation. A total bacterial richness of 664 genera was
found, but variance between individuals arose primarily from differences in the relative abundance
of 14 core genera. Consistent with previously characterized enterotypes [13], bacterial taxa with the
largest variation in abundance were Prevotella, Bacteroides, and Ruminococcaceae. Prevotella correlated
with softer type stools, while Ruminococcaceae was the dominant family in hard type stools. Overall
species richness declines with shorter gut transit times and the abundance of core species increases,
likely because specific bacteria are selected for with a fast growth potential or high degree of mucosal
adherence to avoid washout [221,222]. Other factors that turned out to be microbiome covariates
were recent smoking history as well as the use of antibiotics, osmotic laxatives, IBD drugs, and
antidepressants [221]. In a recent mouse study, six days of treatment with over-the-counter laxative
polyethylene glycol had long-term effects on the gut [223]. Bacterial family S24-7 went from 50% of total
microbial abundance to apparent extinction, while family Bacteroidaceae, also in order Bacteroidales,
experienced an expansion from 20% to 60% microbial abundance. Osmotic stress was observed to
decimate the mucus barrier and cause the immune system to generate a lasting antibody response
against commensal bacteria [223]. Fecal samples were recently collected from 758 Korean men to
examine the effects of cigarette smoking on the microbiome [224]. While no differences were observed
between former smokers and those who never smoked, current smokers had an increased proportion
of Bacteroidetes and decreased levels of Firmicutes and Proteobacteria.
Notable dietary covariates in the Belgian population study included consumption of fruits, alcohol,
meat, soy products, and soda as well as one’s preference for dark chocolate [221]. Surprisingly, mode
of birth and history of breastfeeding were not associated with one’s adult microbiota composition,
and household pets only predicted a minimal fraction of microbiome variation [221]. An earlier
study showed that household dogs primarily alter their owner’s skin microbiota rather than the gut
microbiota [225]. More dominant influencers of the microbiome are the urbanization of outdoor
areas, increased building confinement, and cleaning, each of which diminish overall microbial
diversity, shifting from gram-positive (e.g., Actinobacteria) to gram-negative and potentially pathogenic
species [226–228].
Consistent with the Belgian [221] and other studies [7,120], earlier analysis of the Dutch population
cohort revealed that bacterial taxa could explain BMI and blood lipids independent of age, gender,
and host genetics [229]. Species richness was negatively correlated with both BMI and triglycerides
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and positively correlated with protective levels of HDL cholesterol [120,229]. A significant correlation
is not observed, however, between gut microbiota and LDL or total cholesterol levels [7,120,221,229].
The absence of correlation between plasma LDL and the microbiome is notable given that the latter
is associated with metabolic disease. Despite plasma LDL being used as the principal target in
lipid-lowering therapy for the last three decades, recent evidence suggests that triglyceride, HDL, and
apolipoprotein B blood levels may be more useful CVD predictors [230–235]. Many factors confound
the relationship between plasma LDL concentration and CVD. While one in three individuals are
hyper-responders to dietary cholesterol, the ratio of LDL to HDL is minimally affected when others,
particularly the elderly, consume an additional 100 mg/day [236]. For individuals with similar LDL
concentrations, a predominance of small dense LDL particles (sdLDL) increases one’s CVD risk [236],
as does a higher proportion of covalently modified LDL particles, known as lipoprotein(a) [237].
Widely prescribed statin drugs are effective at lowering LDL and to some extent apolipoprotein B
concentration, but they do not decrease the proportion of sdLDL and have been found to raise plasma
lipoprotein (a) by up to 20%, contributing to what has been termed “residual” CVD risk [238,239]. The
lack of an association between plasma LDL concentration and the microbiome is not surprising given
these confounding factors.
6.2. FODMAPs and Gut Health
Fermentable oligosaccharides (fructans, GOS), disaccharides (lactose), monosaccharides (fructose),
and polyols (sorbitol, xylitol) are termed FODMAPs [240]. Consumption of dietary FODMAPs pulls
water into the small intestine and colon, causing luminal distension. Fermentation of FODMAPs by
gut bacteria and yeast then produces hydrogen or methane gas. Restricting FODMAPs in one’s diet
has been shown to help alleviate functional GI symptoms in IBS patients (bloating, abdominal pain,
diarrhea), but no effects have been reported for intestinal inflammation in IBD [27,240]. Wheat, rye
and barley contain fructans and supply much of the FODMAPs contained in the Western diet. A
double-blind crossover challenge was conducted of 59 adults self-reporting non-celiac gluten sensitivity
(NCGS), who had previously followed a gluten-free diet for at least six months [241]. Participants
completed three seven-day challenges in which a muesli bar was consumed containing either FOS,
wheat gluten, or placebo, with the amounts of fructan/gluten equal to that contained in four slices
of wheat sandwich bread. IBS symptom scores worsened in the fructan challenge (P = 0.04), while
symptoms were actually slightly improved relative to placebo upon consumption of gluten (P = 0.55).
The finding that fructans are responsible for GI symptoms in self-identified NCGS patients, and not
gluten, is also supported by a crossover trial in which 37 subjects with NCGS and IBS followed a
low-FODMAP diet before switching to a high- or low-gluten diet [242]. Regardless of the source of
symptoms, NCGS and IBS at least have overlapping features and are not entirely separate entities [243].
Long-term implementation of a low-FODMAP diet is problematic due to the restriction of healthy
plant foods and the fact that FODMAPs are prebiotics that support gut microbiota. Apples, pears, and
stone fruits are high in fructose and other FODMAPs. Legumes and pulses are also high FODMAP,
as are several vegetables including onion, garlic, and cauliflower. When administered properly by
a trained dietitian, the FODMAP elimination diet is intended to be a process rather than a rigid
exclusion diet. The initial elimination phase lasts 2–6 weeks in order to get GI symptoms under control.
In the challenge phase, specific foods or types of FODMAPs are reintroduced one at a time and in
increasing amounts. The patient is instructed to keep a detailed food diary so they can learn what
FODMAPs are best tolerated and can eventually be incorporated into the final integration phase
of the diet. Two clinical challenges can occur during this process: a patient’s symptoms may not
respond, or they do respond and then the patient becomes reluctant to reintroduce FODMAPs [244].
While long-term studies are lacking, following a low-FODMAP diet reduces the diversity and quality
of dietary components being consumed [245], and healthy diet diversity has been linked to more
diverse microbiota and better health outcomes [246]. Short-term FODMAP restriction has been shown
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to disturb the gut microbiota in as little as 2–3 weeks, reducing total bacterial abundance and the
population of Bifidobacterium, while increasing the ratio of Firmicutes to Bacteroidetes [247,248].
6.3. Ketogenic Diet
KD and low-carbohydrate diets have become a popular and effective tool for losing weight and
can improve blood CVD parameters in the short-term [249,250]. However, 20-year studies involving
a large prospective cohort reveal that diet quality and the source of protein and fat can ultimately
determine health outcomes in low (40% of caloric intake) carbohydrate diets [251,252]. In research by
de Koning et al., it was found that high plant-based intake of protein and fat reduces the hazard ratio
(HR) for T2D to 0.78, whereas high intake of animal protein and fat maximizes the risk (HR: 1.37) [251].
Adjusting for red and processed meat intake was observed to lower the association with animal sources
(HR: 1.11). In strict KD, below ground vegetables and legumes high in net carbs, and most fruits, are
restricted in order limit total carbohydrate intake to 50 g/day. Restricting plant-based carbohydrates
can have considerable effects on gut microbiota given that fiber and prebiotics are required for bacterial
diversity [65,119,208]. The reduction in fiber can also contribute to constipation, a common side effect
of KD.
In an anti-seizure mouse model, KD was shown to reduce gut bacterial alpha diversity, while
elevating the relative abundance of A. muciniphila, but KD was only followed for three weeks [67]. A
much longer study of 10 multiple sclerosis patients found that total bacterial abundance and diversity
decreased in the short-term but recovered during weeks 12–24 of KD treatment [253]. Akkermansia was
observed to increase initially but then declined during long-term KD and pioneer bacteria steadily
declined [253]. Pioneer bacteria such as Bifidobacterium and Clostridium are the first to colonize newborns
and patients recovering from a course of antibiotic treatment. Twenty children with refractory epilepsy
were recently treated with KD for six months [254]. Treatment lowered alpha diversity and decreased
the Firmicutes/Bacteroidetes ratio. In 10 of the children who were non-responsive to treatment (<50%
seizure reduction), the relative abundance of Ruminococcaceae and Clostridia became enriched,
suggesting specific bacteria may serve as an efficacy biomarker or potential therapeutic target [254].
Such alterations in gut microbiota associated with long-term KD suggest the importance of a properly
balanced, high quality diet [65].
6.4. Role of Carbohydrate Intake
Consuming excess carbohydrates as part of a Western diet high in refined grains, starch, and
added sugar negatively impacts gut microbiota. The first connection between the microbiome and
metabolic health was noted in 1970, when the International Sugar Research Foundation found that a
high-sugar diet led to high serum triglycerides in conventional rats but not germ-free rats [255]. In
a modern Dutch population study, the largest dietary predictor of low gut bacterial diversity was
the total intake of carbohydrates, followed by consumption levels of beer, bread, and soda [120].
A study of 178 elderly subjects by Claesson et al. found that patients in long-term residential care
consumed a diet higher in fat and lower in fiber than seniors living in their community [246]. Diet
diversity was scored using the healthy food diversity index, which differentiates between healthy and
unhealthy foods across all food groups, and found to positively correlate with gut bacterial diversity.
Individual microbiota clustered based on long-term care or community living status, and microbiota
composition significantly correlated with frailty, co-morbidity, and inflammation markers [246]. While
obesity research has traditionally compared low versus high fat diets, a rat study found that a
low-fat/high-sucrose diet led to reduced bacterial diversity, increased Firmicutes: Bacteroidetes, a
bloom in Ruminococcaceae, gut inflammation, altered vagal gut-brain communication, and obesity,
similar to an isocaloric high-fat/high-sucrose diet [105].
Diets high in total carbohydrates and sugar correlate with increased fungus Candida and
methanogen Methanobrevibacter, genera from different domains of life that correlate negatively with
consumption of amino acids, protein, and fatty acids [256]. Methanobrevibacter smithii is the most
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prevalent archaeon in the human gut and can comprise up to 10% of all anaerobes in healthy adults.
In a mouse model, M. smithii has been shown to increase host adiposity by directing Bacteroides
thetaiotaomicron to ferment plant polysaccharides (fructans) in the diet to the SCFA acetate [257].
Bacterial fermentation of undigested dietary polysaccharides into SCFAs is estimated to account for 5
to 10% of daily caloric intake in the typical diet [258]. Elevated M. smithii has also been identified in
IBS patients, especially those with IBS-C, in whom methane gas delays gut transit [259]. M. smithii
copy number was observed to correlate inversely with stool frequency (R = −0.42).
Candida are the predominant fungal species capable of colonizing the gut. Overall the mycobiome
is less stable than the microbiome [260]. While bacterial population structure primarily associates
with long-term diet [14,246], Candida can vary extensively in time in response to recent carbohydrate
consumption, antibiotic use, and environmental sources [22]. In a study of 98 healthy volunteers
by Hoffmann et al., Candida correlated positively with long-term intake of total carbohydrates and
sugar, and was strongly associated with recent carbohydrate intake [256]. Unlike Candida and
Methanobrevibacter, bacterial populations were observed to associate more strongly with long-term
dietary habits than with recent food consumption. Prevotella and Ruminococcus increased with
carbohydrate intake and decreased with animal products, while the reverse effect was observed for
Bacteroides [256]. A model of syntrophy was proposed in which methanogenesis supports Ruminococcus
metabolism and Candida degrades starch into simple sugars, allowing for substrate fermentation by
Prevotella.
Stool sample studies have found Candida in 63% of individuals, with 11% showing Candida
overgrowth [261]. Overgrowth can lead to invasive, systemic fungal infection in cancer patients
or immunocompromised individuals, resulting in a high mortality rate. In a mouse chemotherapy
model, C. albicans infection was observed to drive mucosal dysbiosis, allowing Stenotrophomonas,
Alphaproteobacteria, and lactic acid-fermenting Enterococcus to proliferate while bacterial diversity
declined [262]. Antibiotic treatment is also a strong risk factor for systemic candidiasis. In cell growth
assays, SCFAs and lactic acid are shown to have a fungistatic but not fungicidal effect, suggesting
that a healthy microbiome prevents Candida overgrowth [263]. Lactic acid is responsible for the
antimicrobial activity of lactobacilli towards pathogens. Beneficial probiotic strain L. rhamnosus GG
was additionally shown to bear an exopolysaccharide that interferes with Candida growth, hypha
formation, and intestinal adhesion [264].
Excessive sugar or starch consumption can lead to Candida dysbiosis. Candidiasis is mostly
attributed to C. albicans, a species which has intrinsic resistance to the fungistatic effect of SCFAs.
Interestingly, SCFA resistance is dependent on monomeric glucose being present in the growth media;
growth rates are attenuated when the disaccharide maltose is used as a nutrient source [263]. In a
study of 120 individuals with chronic intestinal Candida overgrowth, diet therapy cured 85% of patients
three months after conventional antifungal therapy, compared to 42% of subjects receiving nystatin
alone [261]. Patients in the diet group avoided foods high in simple sugars and starch, cured and fatty
meats, milk and dairy products, and alcohol.
The notion of cutting starch and sugar to promote intestinal health can be traced to the 1920s,
when gastroenterologist Sydney Haas began treating celiac patients using the specific carbohydrate
diet (SCD) [265]. SCD was later popularized as a diet for reducing microbial overgrowth by biochemist
Elaine Gottschall, who created a dictionary of legal/illegal foods and ingredients [266,267]. The
diet prohibits grains (wheat, barley, oats, rice, corn), potatoes, processed meats, added sugars, and
disaccharides (lactose, sucrose), while allowing fresh (not canned) fruit, vegetables, and juices not
from concentrate [268]. SCD limits dairy to butter, eggs, and aged cheeses containing minimal lactose.
Beer, sweet wine, liqueurs, and mucilaginous fibers are restricted as are additives and preservatives
like maltodextrin, pectin, guar/gums, and FOS. Sugar alcohols are prohibited, and honey is the
recommended sweetener in SCD. A strict three-month period is first observed to starve off overgrowing
bacteria and yeast, after which legumes may be selectively introduced. Unlike a low-FODMAP dietary
strategy, SCD is intended to be a long-term exclusion diet. While avoiding FODMAPs can improve IBS
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symptoms in the short-term, cases of drug-free clinical remission have been reported in IBD patients
following SCD, with complete resolution of mucosal inflammation in some Crohn’s patients [27,269].
Artificial food ingredients are specifically being linked to gut dysbiosis. Maltodextrin, a
polysaccharide derived from starch hydrolysis, is a common food additive that enables adherent
invasive strains of E. coli to adhere to intestinal epithelial cells and grow into biofilm, contributing to
gut dysbiosis and intestinal inflammation [21]. Polysorbate-80, an emulsifier used in processed foods,
has been shown to enhance translocation of pathogenic E. coli strains across colonocytes [21]. In a
mouse study by Chassaing et al., low (0.1–1.0%) mass concentrations of emulsifiers polysorbate-80 and
carboxymethylcellulose induced low-grade inflammation, obesity, and dysglycemia in wild-type mice
and promoted robust colitis in mice predisposed to the disorder [270]. Fecal transplants to germ-free
mice demonstrated that changes in microbiota were responsible. The emulsifiers reduced microbial
diversity and levels of health-promoting Bacteroidales, while increasing mucolytic Ruminococcus
gnavus and pro-inflammatory Proteobacteria. Reduced mucus thickness was also observed in the
emulsifier-treated mice, along with bacterial encroachment into the normally sterile inner mucus
layer [270]. Microbiota encroachment has been implicated in IBD and metabolic syndrome. In humans,
the average bacterial-epithelial distance of closest bacteria correlates inversely with BMI, fasting glucose
levels, and hemoglobin A1c [271]. Such observations point to the consumption of processed foods as
one potentiator of the global obesity epidemic [272].
6.5. Intermittent Fasting
Excessive caloric intake results in fat being stored in white adipose tissue, while energy expenditure
by fat oxidation predominantly occurs from thermogenesis of brown adipose tissue. Conversion of
white adipocytes, known as beiging, is thus a promising strategy for treatment of metabolic disease.
Recently, Li et al. were able to selectively induce the beiging of white adipose tissue in mice using the
natural strategy of intermittent fasting [273]. Mice placed on an every-other-day fasting regimen had the
same cumulative food intake as the ad libitum control group, but experienced a shift in gut microbiota,
increase in fermentation products acetate and lactate, and a reversal of diet-induced obesity. Transport
of acetate and lactate across the adipocyte membrane is driven by monocarboxylate transporter 1,
whose expression was found to be upregulated in beige cells. Beiging was not observed in germ-free
mice, but could be restored upon fecal transplantation of gut microbiota [273]. A previous study in
mice demonstrated that cold exposure activates white fat beiging and increases insulin sensitivity via
changes in the microbiome [274]. These observations reveal the existence of a microbiota-beige fat axis.
In other work, Panda et al. found that diet-induced obesity dampens daily cyclical fluctuations in mice
microbiota [275]. Restricting feeding to an eight-hour window each day partially restored circadian
fluctuations, including a decrease in the abundance of Lactobacillus observed during the feeding phase.
Intermittent fasting, longer multiday fasts, and fasting-mimicking diets have been shown to improve
gut barrier function, increase microbial diversity, enhance antioxidative microbial pathways, and even
reverse intestinal inflammation in models of IBD [276–278].
7. Other Considerations
7.1. Endocannabinoid System
In addition to altered microbiota and low-grade inflammation, obesity is characterized by increased
endocannabinoid (eCB) system tone. A study of the eCB system in lean and obese mice was performed
by blocking or activating cannabinoid receptor 1 (CB1) [279]. SR141716A, a CB1 antagonist that reduces
food intake, significantly reduced gut permeability and plasma LPS levels in obese mice, decreasing
both adiposity and blood glucose levels. In contrast, agonist HU-210 increased eCB system tone
in lean mice and raised plasma LPS. Increased gut permeability with HU-210 was attributed to a
decrease in the expression of two epithelial tight junction proteins. By comparing diet-induced obesity
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and intervention with antibiotics or prebiotics, microbiota associated with obesity were shown to be
responsible for increasing the expression levels of CB1 in colonocytes and adipose tissue [279].
Endocannabinoids are an appealing therapeutic strategy for many conditions such as treating
inflammation in IBD [280]. Cannabinoid antagonist cannabidiol has been shown to counteract the
inflammatory environment induced by LPS in mice and in human colonic cultures derived from
ulcerative colitis patients, at least in part due to PPAR-γ activation [281]. The use of CB1 agonists
has been proposed for increasing GI transit time in IBS-D, while antagonists could prove useful for
IBS-C [282]. Partial agonist tetrahydrocannabinol (THC) increases food intake in the short-term, but
in epidemiological surveys, obesity is observed to be less prevalent among cannabis users [283]. In
mice fed a high-fat diet, chronic treatment with THC was recently shown to stave off increases in the
ratio of Firmicutes to Bacteroidetes, increase the abundance of A. muciniphila, and prevent diet-induced
obesity [284].
7.2. Medication Dysbiosis
Oral administration of high dose antibiotics can result in rapid changes to gut microbiota and is
implicated in dysbiosis [22,285–287]. Over-the-counter and prescription non-antibiotic medicines also
influence the gut microbiome. Proton pump inhibitors (PPIs) are a widely used class of drugs that
function by raising gastric pH. PPIs are an effective short-term indicated therapy for gastroesophageal
reflux, peptic ulcers, and H. pylori infection, but many chronically afflicted patients take long-term
or off-label dosing. Meta-analyses have shown that PPI use increases the risk of developing SIBO
and C. difficile infection (odds ratios: 1.71 and 1.99; 95% confidence intervals: 1.20–2.43 and 1.73–2.30,
respectively) [288,289]. Antibiotics, PPIs, and atypical antipsychotics have each been implicated in
reducing alpha microbial diversity [286,290,291]. Second-generation antipsychotic medications, which
contribute to weight gain and metabolic syndrome, gradually increase the ratio of Firmicutes to
Bacteroidetes in association with BMI and decrease the abundance of Akkermansia [292,293]. Efforts
are now underway to examine how bacterial taxa each respond to treatment with drugs from other
common therapeutic classes [290,294]. Opioids can cause severe constipation and at high doses in mice
enable bacterial translocation through disruption of the gut barrier [290,295]. Changes in microbiota
have been implicated in the creation of intestinal lesions by nonsteroidal anti-inflammatory drugs,
which reduce blood flow to the gut and weaken the hydrophobic mucosal barrier. Lastly, GI symptoms
are a common side effect of statins, which affect bile acid metabolism and have been shown to increase
the abundance of five bacterial families including Enterobacteriaceae [290].
The interrelationships discussed in this article between diet, environmental factors, gut microbiota,
and their physiological outcomes are summarized in Table 1.
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Table 1. Summary of diet-microbiota interactions in health and disease.
Healthy Microbiota Gut Dysbiosis Other Cause/Consequence
High dietary fiber intake [115] Western diet; low core diversity[10,83]
High in choline/fat/added sugar
[105,117]
Plant foods low in choline [151] High [TMAO] in blood [134] Arterial plaque formation [135]
Fruits and vegetables;
prebiotic-containing foods [4]





High α species diversity;
butyrate-producing [4,105,120]
Low short-chain fatty acid
fermentation [100] Intestinal inflammation [25,117]
Anti-inflammatory omega-3 [217] Diet high in omega-6 fatty acids Pro-inflammatory [149]
Lean body mass, increased
lipolysis [84]
Obesity, vagal remodeling,










Glucose and lipid homeostasis
[100]
Insulin resistance, bacterial









Gut-brain interactions [78] Mental health issues or visceralpain [72,296]





Structural or functional bowel
disorders [22,50] Colorectal cancer [3]
Healthy fecal biomarkers [53] Need butyrate/inulinsupplementation [81,104,213]








8. Conclusions and Future Directions for Research
The past decade of research has begun to reveal the overarching roles the gut microbiome plays
in human health. Particular species of Bifidobacterium, Akkermansia, and Lactobacillus are beneficial to
the human host and are included in many probiotic preparations, but genera such as Bacteroides and
Ruminococcus are implicated in negative health outcomes. Antibiotic use and modern sanitation have
contributed to a decrease in the diversity of the human microbiome [287]. Core microbial diversity
and the ratio of Firmicutes to Bacteroidetes are general indicators of health and may change with age,
though inter-individual variation is large and quality of diet and environmental factors play a dominant
role [246,297–299]. Future research will need to characterize the changes in bacterial composition
accompanying different disease states and the corresponding expression patterns in genes of both
microbe and host [296,300]. Increased age is associated with oxidative stress and a pro-inflammatory
state, and improvements in microbiota have been shown to extend life span in animal models of
aging, though human aging studies are lacking [81,278,301,302]. Prebiotics and dietary fiber increase
the relative abundance of beneficial anaerobic bacteria, increase butyrate fermentation, and have
favorable metabolic effects. Propionate, on the other hand, is an SCFA used as a food preservative
that has recently been linked to insulin resistance when consumed in typical concentrations [303].
Lastly, negative results are being reported for gut microbiota-produced acetate. In rats fed a high-fat
diet, increased acetate production was found to promote obesity and metabolic syndrome [304]. In
an analogous rat model, colonic infusion with resistant starch plus exogenous acetate delayed the
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development of obesity and insulin resistance and protected the mucosal barrier [305]. Genera such
as Faecalibacterium and Roseburia were observed to enable the conversion of acetate into butyrate,
increasing serum and fecal butyrate levels.
While our knowledge of commensal and pathogenic bacteria has grown considerably, future
research will need to further address the role of nonbacterial microbes in the human gut, including
viruses, eukaryotes, yeasts, and archaea [256,306,307]. Viruses parasitic to bacteria, known as
bacteriophages, have been shown to coexist over time with the bacterial species they prey on. Phage
predation can also lead to cascading effects on other species, including blooms in non-targeted
bacteria [308]. An abnormal enteric virome has been found in IBD patients, in whom an increase
in bacteriophage richness contributes to decreasing bacterial diversity and gut dysbiosis [309]. The
most prevalent eukaryote in the human intestine, Blastocystis, is a single-celled heterokont protist that
colonizes a considerable fraction of individuals in industrialized (0.5–30%) and developing (30–76%)
nations [310]. It has been hypothesized that Blastocystis can prey on bacterial species in the gut in its
ameboid form [306] and can contribute to the pathogenesis of IBS [311]. In a mouse study by Yason et
al., infection with a pathogenic subtype of Blastocystis (ST7) was observed to decrease intestinal levels
of beneficial Bifidobacterium and Lactobacillus while increasing E. coli content, seeming to fulfill Koch’s
postulate that infection of a healthy individual leads to disease [312]. In asymptomatic individuals,
however, nonpathogenic Blastocystis correlates positively with microbial diversity and inversely with
BMI, fecal calprotectin levels, Crohn’s disease, and colorectal cancer [313]. As a genus, species of
Blastocystis have incredibly divergent genomes. The percentage of proteins unique to each subtype
ranges from 6% to 20%, and orthologous proteins have a median amino acid sequence identity of only
60% [314].
Diet and nutritional status are important determinants in human health. Efforts to characterize
the relationship between diet and health have pivoted from studying the effects of individual nutrients
to examining the roles of dietary patterns and specific diets [149–151]. The role of diet in shaping gut
microbiota, host metabolism, and lipid homeostasis is changing our view of the steps a person can
take to make improvements in their systemic health [10,315]. Correlations between microbial diversity
across as many as 60 different dietary covariates reveal the importance of a high quality, balanced
diet [120], supporting the view that dietary supplementation of individual nutrients does not take
the place of a sound diet [316]. Observations that individual foods stimulate the growth of specific
bacterial taxa suggest that intestinal bacteria could actually be serving to guide our food preferences,
appetite, and feelings of satiety [221,317]. By influencing metabolism and inflammation, diet and
nutrition can outweigh genetic and environmental factors in determining health outcomes for chronic
Western conditions such as diabetes, obesity, IBS, IBD, colorectal cancer, and depression [1,2,318].
One research question that remains is what constitutes an optimal health-promoting microbiome,
and how individuals with different starting microbiota can achieve such microflora. In characterizing
gut eubiosis and dysbiosis, the effects of particular microbial species cannot be considered simply in
isolation, giving rise to the notion of ecological Koch’s postulates of disease causation [162]. Changes in
stool consistency and water content have hampered quantification of absolute microbial loads, and new
methods are needed to identify pathological markers [319]. While fecal samples are generally thought
to be representative of colonic microbial communities, further research is needed to characterize the
different microbial communities that occur along the length of the GI tract [320]. A study of five gut
sections taken from pigs found a predominance of Lactobacillus in the small intestine and Prevotella in
the colon, suggesting that rapid utilization of simple carbohydrates drives microbial competition in the
upper intestine, while polysaccharide fermentation is left mainly to the colon [321].
Inter-individual variation in gut microbiota could explain the disparity in outcomes often observed
with lifestyle interventions and why one-size-fits-all diets are not always effective [83,125,201]. The
influence of diet type on the relative abundances of microbial populations can be complex and
difficult to reproduce across different clinical studies, in part due to the number of individual species
involved in each phylum and genus [142]. Individuals have been shown to have highly personalized
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microbiome responses to different foods depending on their prior history of dietary diversity [322].
Rapid modifications in gut microbiota are possible when adopting a new dietary strategy, such as
following an exclusively plant- or animal-based diet [323]. Microbial markers have even been proposed
as an objective means of measuring adherence to a given dietary pattern in order to more accurately
correlate resultant health outcomes [150]. Microbes collectively encode 150-fold more genes than the
human genome [5]. Enzymes in gut bacteria across the main taxonomic groupings have been shown to
metabolize 176 common oral drugs, suggesting that differences in gut microbiota may shape individual
responses to drug therapy [324]. Ultimately, determining the full landscape of host-microbiota
interactions will enable advances in personalized medicine, precision nutrition [125,325], and the
development of next-generation probiotics tailored to the individual [326].
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GPCR G-protein coupled receptor
GPR109A niacin receptor 1
GPR41 free fatty acid receptor 3
HR hazard ratio
HDL high-density lipoprotein
IBD inflammatory bowel disease
IBS irritable bowel syndrome
IBS-C IBS with predominant constipation
IBS-D IBS with predominant diarrhea




NAS non-caloric artificial sweetener
NCGS non-celiac gluten sensitivity
P probability value
PPAR-γ peroxisome proliferator-activated receptor gamma
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PUFA polyunsaturated fatty acid
R Pearson correlation coefficient
RYGB Roux-en-Y gastric bypass
SCD specific carbohydrate diet
SCFA short-chain fatty acid
sdLDL small dense low-density lipoprotein particle
SGLT1 sodium glucose cotransporter-1




TNF tumor necrosis factor
T2D type 2 diabetes
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